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Purpose
We tested the hypothesis that juvenile dermatomyositis
(JDM) disease course in children with disease onset at or
below age three years may be different than that of chil-
dren with disease onset at greater than three years of age.
Methods
Institutional Review Board approval was obtained to retro-
spectively review the charts of 78 patients with JDM seen
in pediatric rheumatology clinic at Nationwide Children’s
Hospital over the past 23 years. These patients were age
0-18 years with 19 patients at or below age three years at
onset, and 59 above age three years at onset. The data
regarding disease course and outcome were collected as of
the last clinic follow-up or July30, 2010, whichever came
first. Wilcoxon 2-sample test was used to compare contin-
uous variables between the two age groups. Chi-square
test and Fisher’s exact test were used to compare categori-
cal variables between the two age groups.
Results
The mean ages of onset in the two groups were 27
months and 91 months. The mean times between onset
of symptoms to diagnosis in younger and older age
groups were similar at 5.6 months and 4.5 months,
respectively. The younger group had more females
(p=0.05), were more likely to have a family history of
autoimmune diseases (p=0.012), and were less likely to
have disease onset during the typical winter-spring sea-
sons (p = 0.031). The younger group was more likely to
have a preceding fever (p=0.029), and less likely to have
the following at diagnosis: heliotrope rash (p=0.04),
Gottron’s sign (p=0.049), any rash (p=0.0495), nailfold
capillary loop abnormalities (p=0.010), elevated creati-
nine kinase (p=0.022), elevated aspartate aminotransfer-
ase (p=0.021) and elevated aldolase (p=0.0353). Among
those who had muscle biopsy at diagnosis, the younger
children were more likely to have atypical histopathology
(p=0.002). The younger group was treated more often
with pulse methylprednisolone (p=0.0434), and less often
with hydroxychloroquine (p=0.0351). There were no dif-
ferences between the two groups in the initial oral corti-
costeroid dose (p=0.8017), treatment with methotrexate
(p=0.709), and treatment with other immunosuppres-
sants (p=0.323). There was no difference in the mean
duration of methotrexate therapy (p=0.102), but the
younger group had a shorter mean (p=0.038) and maxi-
mum (p=0.026) time on oral steroids. The two groups
had similar proportions of patients with remission and
active disease at 1 and 5 years. The younger patients
were less likely to have active disease 10 years post diag-
nosis (p=0.019) and more likely to experience a mono-
cyclic course (p=0.027).
Conclusion
There were significant differences between JDM patients
with disease onset at or below age three years, compared
to their older counterparts. Younger patients in our
cohort had fewer typical findings at diagnosis. They
were more likely to experience a monocyclic course, a
shorter total disease course, and a shorter duration of
oral corticosteroid therapy.
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